NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 41.7% and is now trading at $3.71. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences Inc (NASDAQ:NERV) issued its quarterly earnings data on Monday, May, 4th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.05. View Minerva Neurosciences' earnings history.

6 analysts have issued 1-year target prices for Minerva Neurosciences' shares. Their forecasts range from $2.00 to $26.00. On average, they anticipate Minerva Neurosciences' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price. View analysts' price targets for Minerva Neurosciences.

News articles about NERV stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutMinerva Neurosciences.

Minerva Neurosciences saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,820,000 shares, a drop of 5.4% from the April 30th total of 2,980,000 shares. Based on an average trading volume of 392,500 shares, the short-interest ratio is presently 7.2 days. Approximately 9.0% of the shares of the stock are short sold. View Minerva Neurosciences' Current Options Chain.

Some companies that are related to Minerva Neurosciences include Passage Bio (IMRA), Frequency Therapeutics (FREQ), Athersys (ATHX), Aprea Therapeutics (APRE), Dynavax Technologies (DVAX), Trillium Therapeutics (TRIL), Passage Bio (KROS), Corbus Pharmaceuticals (CRBP), Crinetics Pharmaceuticals (CRNX), Basilea Pharmaceutica (BPMUF), Clovis Oncology (CLVS), AC Immune (ACIU), AnaptysBio (ANAB), Atreca (BCEL) and Viking Therapeutics (VKTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences.

NERV stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $3.71.

Minerva Neurosciences has a market capitalization of $145.51 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]